UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $110.6
UBS Remains a Buy on Alcon (ALC)
Buy Rating Affirmed: Alcon's Growth Prospects Bolstered by Unity VCS and New Product Pipeline
BTIG Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $104
Alcon Is Maintained at Buy by BTIG
Berenberg Bank Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $110.07
Alcon (ALC) Gets a Buy From Berenberg Bank
Alcon Analyst Ratings
RBC Capital Upgrades Alcon(ALC.US) to Buy Rating, Raises Target Price to $118.36
Alcon Raised to Outperform From Sector Perform by RBC
Alcon Target Raised to CHF100 From CHF85 by RBC
Citi Maintains Alcon(ALC.US) With Buy Rating, Announces Target Price $116
CFRA Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $102.73
Morgan Stanley Remains a Hold on Alcon (ALC)
Oppenheimer Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $110
BofA Securities Maintains Alcon(ALC.US) With Hold Rating, Raises Target Price to $99.89
J.P. Morgan Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $99.07
Analysts Conflicted on These Healthcare Names: Alcon (ALC) and Telix Pharmaceuticals Ltd. (OtherTLPPF)
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $98 to $120.85
Oppenheimer Sticks to Their Buy Rating for Alcon (ALC)